An IndieGoGo campaign has launched to raise funds to progress research & development DRACOs against clinically relevant viruses. The campaign launched Oct 13th and will last for 60 days.

Boston, MA (PRWEB) October 14, 2015

An IndieGoGo crowdfunding campaign was started to fund the advancement of Dr.Rider's DRACOs research. DRACOs have shown promising results as a broad spectrum antiviral and, with the NIH grant completed, requires additional funding to progress research against a clinically relevant virus that may eventually lead to human clinical trials.

Dr. Todd Rider from MIT invented DRACOs (Double-stranded RNA Activated Caspase Oligomerizers). DRACOs are novel broad-spectrum antiviral drugs that have the potential to revolutionize the treatment and prevention of virtually all viral diseases. So far, DRACOs have cured 18 viruses in laboratory tests. DRACOs have proved effective against Rhinovirus (the common cold), Dengue virus, H1N1 Influenza (Swine Flu) and more in the lab. Results have been published in the Journal of PLOS ONE (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0022572).

Just as the development of antibiotics revolutionized the treatment and prevention of bacterial infections in the mid-20th century, MIT’s Dr. Todd Rider has invented DRACOs, a novel broad-spectrum antiviral drug that has the potential to revolutionize the treatment and prevention of virtually all viral infections. Dr. Rider’s DRACOs approach and results have been called “visionary” by the White House (National Bioeconomy Blueprint, April 2012, p. 9), named one of the best inventions of the year by Time magazine (November 28, 2011, pp. 58, 78), and featured on the BBC Horizons TV program (2013).

advertisement | advertise on newsday

However, research on DRACOs has entered the well-known “Valley of Death” in which a lack of funding prevents DRACOs, and many other promising new drugs, from being developed and advancing toward human medical trials. To progress DRACOs research it needs to be demonstrated against clinically relevant viruses (i.e; HSV). To that end an IndieGoGo campaign (http://igg.me/at/EndTheVirus) was started on October 13, 2015.

Funds raised by the IndieGoGo campaign will be used to test, optimize and develop DRACOs against Herpes viruses. In particular: HSV (Cold Sores and Genital Herpes), CMV (Cytomegalovirus), EBV (Epstein-Barr Virus) and KSHV (Kaposi's Sarcoma).

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/10/prweb13018147.htm